Deep Track Capital, LP
Q2 2022 13F-HR Holdings
Net value change ($000)
-38,159
(-2.4%)
New positions
6
Sold out positions
6
Turnover %
17.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| BMRN | 54,227 | NEW |
| Global Blood Therapeutics, Inc. | 36,678 | 45.9% |
| NUVB | 31,089 | 511.5% |
| NRIX | 30,866 | NEW |
| ACAD | 24,420 | NEW |
| INOZYME PHARMA INC | 15,503 | NEW |
| SDGR | 14,842 | NEW |
| ACET | 13,024 | NEW |
| KURA | 12,919 | 23.5% |
| Forma Therapeutics Holdings, Inc. | 12,470 | 80.8% |
Top Reduces (Value $000, Stocks/ETFs)
| ALNY | -75,712 | -100.0% |
| KROS | -54,628 | -72.8% |
| BCYC | -32,779 | -40.2% |
| IVERIC bio, Inc. | -32,445 | -42.8% |
| FATE | -27,534 | -35.5% |
| Sage Therapeutics, Inc. | -16,794 | -75.2% |
| Jounce Therapeutics, Inc. | -16,016 | -55.4% |
| FDMT | -15,100 | -40.8% |
| CRNX | -14,203 | -42.0% |
| ENTA | -14,146 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
74,971
(4.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|